

Table S1. Serum level of CEA and CA 19-9 and clinical patient characteristics					
Variables	Serum level of CEA		Serum level of CA19-9		
	(n=545)		(n=494)		
	<5 µg/L	≥5 µg/L	<35 kU/L	≥35 kU/L	
	n (%)	n (%)	n (%)	n (%)	
WHO performance status					
0	83 (23)	284 (77)	148 (45)	180 (55)	
1	11 (7)	144 (93)	38 (26)	107 (74)	
2	2 (9)	21 (91)	2 (10)	19 (90)	
Origin of primary tumour					
Colon	59 (18)	262 (82)	105 (35)	192 (65)	
Rectum	37 (17)	187 (84)	83 (42)	114 (58)	
Surgery of primary tumour					
Resected	79 (21)	290 (79)	147 (44)	187 (56)	
Not resected	17 (10)	159 (90)	41 (26)	119 (74)	
Time of metastases					
Synchronous	60 (15)	329 (85)	109 (31)	238 (69)	
Metachronous	36 (23)	120 (77)	79 (54)	68 (46)	
Type of metastases					
Liver-only	14 (14)	88 (86)	33 (37)	56 (63)	
Lung-only	8 (33)	16 (67)	15 (71)	6 (29)	
Other-sites-only	6 (21)	23 (79)	12 (44)	15 (56)	
Multiple sites	68 (17)	322 (83)	128 (36)	229 (64)	
Alkaline phosphatase level					
Normal	76 (27)	210 (73)	132 (51)	126 (49)	
> UNL	20 (8)	239 (92)	56 (24)	180 (76)	
Platelet count					
≤400/nL	77 (20)	306 (80)	142 (41)	205 (59)	
>400/nL	19 (12)	143 (88)	46 (31)	101 (69)	
White blood cell count					
≤10/nL	87 (21)	326 (79)	161 (44)	208 (56)	
>10/nL	9 (7)	123 (93)	27 (22)	98 (78)	
RAS/BRAF mutation status					
<i>RAS/BRAF</i> wild-type	27* (15)	159* (85)	72† (42)	99‡ (58)	
<i>RAS</i> mutation	40* (20)	161* (80)	65† (36)	114‡ (64)	
<i>BRAF</i> mutation	18* (34)	35* (66)	18† (37)	31‡ (63)	
CRP level					
≤10 mg/L	55† (28)	139† (72)	91§ (52)	85§ (48)	
>10 mg/L	27† (12)	207† (88)	63§ (30)	149§ (70)	

Abbreviations: CRP, C-reactive protein; UNL, Upper normal limit; WHO, World Health Organization.
*Analysed for *RAS/BRAF* mutations (n=440), †CRP (n=428), ‡*RAS/BRAF* mutations (n=399), §CRP (n=388).